论文部分内容阅读
目的:观察健脾祛瘀解毒法联合化疗治疗脾虚毒瘀型非小细胞肺癌的临床疗效。方法:选择60例脾虚毒瘀型非小细胞肺癌患者为研究对象,随机平均分为两组,研究组30例采用中药联合化疗治疗,对照组30例采用单纯化疗治疗。观察治疗3个疗程后患者临床症状改善情况、生活质量评分、肿瘤标志物、凝血系列变化以及不良反应发生情况。结果:治疗3个疗程后,研究组患者的临床症状明显改善,随着服用时间的延长,症状评分逐渐减少,治疗前后相比(P<0.05),两组进行组间比较可见到症状评分改善的明显差异,(P<0.05);研究组患者治疗后较治疗前卡氏评分明显升高,而对照组卡氏评分下降,(P<0.05);两组治疗前后血清CEA水平变化比较差异有统计学意义(P<0.05),研究组优于对照组,CYFRA-21水平变化比较无统计学差异(P>0.05)。在毒副反应方面,恶心呕吐、白细胞减下降程度两组差异均有统计学意义(P<0.05)。结论:健脾祛瘀解毒法联合化疗治疗脾虚毒瘀型非小细胞肺癌,可以提高临床疗效,改善临床症状,改善患者血液高凝状态,减轻化疗不良反应,值得临床推广。
Objective: To observe the clinical effects of combined therapy of invigorating the spleen, removing blood stasis and detoxifying therapy and chemotherapy on non-small cell lung cancer with spleen deficiency syndrome. Methods: Sixty patients with NSCLC were selected as study subjects and randomly divided into two groups. 30 cases in the study group were treated with combination chemotherapy and 30 cases in the control group were treated with chemotherapy alone. Observe the improvement of clinical symptoms, quality of life score, tumor markers, changes of coagulation series and the occurrence of adverse reactions after 3 courses of treatment. Results: After 3 courses of treatment, the clinical symptoms of the study group were significantly improved. With the extension of taking time, symptom scores decreased gradually, compared with before treatment and after treatment (P <0.05). Symptom scores improved (P <0.05). After treatment, the patients in study group had significantly higher Karnofsky scores than those before treatment, while those in control group decreased (P <0.05). There was significant difference in serum CEA levels between the two groups before and after treatment Statistical significance (P <0.05), the study group is better than the control group, CYFRA-21 levels showed no significant difference (P> 0.05). In the side effects, nausea and vomiting, decreased leukopenia two groups were statistically significant differences (P <0.05). Conclusion: Jianpi Quyu detoxification combined with chemotherapy for the treatment of non-small cell lung cancer of the spleen with toxic stasis can improve clinical efficacy, improve clinical symptoms, improve blood hypercoagulability and reduce adverse reactions of chemotherapy, which is worthy of clinical promotion.